Xeljanz Cancer Risks Detailed The degree to which the oral rheumatology drug tofacitinib (Xeljanz) seems to promote new malignancies is now fleshed out in the latest, and at least somewhat reassuring, report from a landmark safety study. https://t.co/OG2OkD5Tcw https://t.co/1dZcJ5jDUj